Haploidentical haematopoietic SCT (HSCT) using T-cell-replete grafts and post-transplant high-dose CY has found increasing acceptance. Our purpose was to evaluate the feasibility and outcome of this strategy as second HSCT incorporating donor change for acute leukaemia relapse after a first allogeneic transplantation. The courses of 20 consecutive adults (median age 37 years, 12 male) with AML (n = 14), ALL (n = 5) and acute bi-phenotypic leukaemia (n = 1) were analysed retrospectively. Conditioning consisted of fludarabine, CY and either melphalan or TBI or tresosulfan+/ -etoposide. Engraftment was achieved in 17 (85%), and a second remission was induced in 15 patients (75%) on day +30. The rate of grade II-IV acute GvHD was 35%, while chronic GvHD occurred in five patients. Most commonly observed grade III-IV toxicities were mucositis (30%), hyperbilirubinemia (20%), elevation of transaminases (20%) and creatinine (20%), while invasive fungal infection affected 30%. One-year non-relapse mortality (NRM) was 36%. At a median follow-up of 17 months, estimated 1-year OS was 45%, and 1-year relapse-free survival was 33%. This strategy was feasible and allowed for successful engraftment with a moderate rate of toxicity. Early outcome and NRM are at least comparable with results after a second HSCT from HLA-matched donors without donor change at HSCT2.
INTRODUCTION
Allogeneic haematopoietic SCT (HSCT) is a potentially curative treatment option for acute leukaemia (AL). Better supportive care, better treatment of GvHD and infections and the introduction of reduced intensity conditioning (RIC) have improved safety and outcome of HSCT. In contrast, little progress has been made with respect to prevention and treatment of post-transplant relapse, which remains the major cause of treatment failure. 1, 2 Although no standard treatment has been defined, therapeutic options included (alone or in combination) conventional chemotherapy, demethylating agents, antibodies, targeted drugs, DLI and second allogeneic transplantation (HSCT2). [3] [4] [5] [6] In HSCT2, most published studies have focussed on the effect of a second transplant from the original donor. 3, 7 Nevertheless, change to another donor for HSCT2 is frequently considered to increase the efficacy of a putative GvL reaction. However, the impact of donor change on outcome is unclear, and available data are limited. [8] [9] [10] Recently, a German study has analysed the effect of donor change in both related and matched unrelated donor (MUD) settings, showing at best a trend towards improved survival after unrelated HSCT1 while a clear advantage in terms of OS could not be demonstrated. 11 The Baltimore group has introduced a novel protocol for HLA-haploidentical transplantation using T-cell-replete grafts, RIC and postgrafting high-dose CY (HDCY) for depletion of allo-reactive T-cells. 12 Low rates of GvHD and non-relapse mortality (NRM) have been reported. 12, 13 So far, few data are available on this approach for the treatment of patients relapsing after autologous and allogeneic HSCT. 12, 14 However, given the poor results to be expected with DLI and conventional HSCT2 from sibling and MUD, haploidentical HSCT2 according to this protocol was performed at two German transplant centres as treatment of choice for all patients with AL relapse after HSCT1. The rapid availability of an HLA partially matched related donor as compared with an alternative MUD and a possible advantage of a stronger GvL effect 15, 16 in the haploidentical setting as compared with both HLA-matched sibling donors and MUD were regarded as possible advantages of this strategy.
Here, we retrospectively report on the feasibility of this strategy and the clinical outcomes in the first 20 consecutive patients.
PATIENTS AND METHODS
Patients with AL relapse after HSCT1 were considered for a HLAhaploidentical HSCT2 based on the following criteria: (1) age ⩾ 18 years (2) Eastern Cooperative Oncology Group score ⩽ 1, (3) adequate renal and hepatic function (creatinine clearance >70 mL/min; serum bilirubin o1.5 ULN (upper limit of normal), glutamat-oxalacetat-transferase (GOT)/ glutamat-pyruvat-transferase (GPT)o2.5 ULN), (4) availability of a HLA-haploidentical related donor and (5) signed informed consent. The study was performed according to the modified Helsinki declaration.
Preparative regimen and supportive care RIC consisted of fludarabine (30 mg/m 2 i.v. per day, over 5 days) and CY (14.5 mg/kg i.v. per day, over 2 days). By analogy to the concept of sequential therapy, which was introduced by our group for HSCT1 in high-risk AML patients, 17, 18 non-remission patients received a sequential strategy of cytoreductive chemotherapy, immediately followed by RIC and HLA-haploidentical HSCT2. Further, the last part of the conditioning was varied on an individual basis, according to the patients' diagnosis, previous treatment and cumulative dose of TBI. GvHD prophylaxis consisted of two doses of CY (50 mg/kg i.v., days +3 and +4) followed by mycophenolate mofetil (4 × 500 mg daily) and tacrolimus (targeted levels between 10 and 12 ng/mL), each starting on day+5. BM was the preferred stem cell source ( Figure 1 ). All patients received standard anti-microbiological prophylaxis. Patients were routinely monitored for virus reactivation and were treated preemptively for CMV and EBV. Ursodeoxycholic acid and unfractionated heparin were administered for prevention of sinusoidobstruction syndrome.
Objectives and statistics
The primary objective was to evaluate the feasibility of the approach. Patients were evaluated for rejection, engraftment, chimerism, acute and chronic GvHD (aGvHD and cGvHD, respectively), toxicity and infection, CR on day +30 and relapse, using standard definitions. [19] [20] [21] [22] Statistical analysis of OS, relapse-free survival (RFS) and NRM were performed by the Kaplan-Meier method 23 using SAS 9.3 (SAS Institute Inc., Cary, NC, USA). Associations between OS and RFS and patients' and donors' characteristics are presented as univariate hazard ratios. P-values and 95% two-sided confidence intervals are reported.
RESULTS

Patient and donor characteristics
Between August 2009 and June 2012, 20 patients with a median age of 37 years (range 21-59) suffering from AML (n = 14), ALL (n = 5) or biphenotypic AL (n = 1) proceeded to haploidentical HSCT2 at the Ludwig-Maximilians University Hospital of Munich (n = 18) and at the Klinikum Augsburg (n = 2).
Patients had relapsed after first HLA-matched related (n = 6), -mismatched related (n = 2) or HLA-MUD (n = 12) transplantation. Conditioning for HSCT1 was myeloablative in five ALL patients and reduced in all others. Median duration of remission after HSCT1 was 350 days (range 45-1634), in 10 patients (50%) remission was o 6 months. Median time from HSCT1 to HSCT2 was 363 days (range 102-2745). The median haematopoietic cell transplantation-comorbidity index 24 at HSCT2 was 2 (range 0-6).
Patient and second donor characteristics are summarised in Table 1 .
Treatment
According to the Baltimore protocol, 12 a T-cell-replete haploidentical graft, immunosuppressive chemotherapy (fludarabine, CY) pretransplant and HDCY, tacrolimus and mycophenolate mofetil post transplant were used as backbone for conditioning and GvHD prophylaxis. Before the start of conditioning, 17 nonremission patients received cytoreductive chemotherapy, consisting of clofarabine in 14, FLAMSA (fludarabine/cytarabine/amsacrine) in 2 and FLAG-Ida (fludarabine/cytarabine/idarubicin) in 1 patient. One patient with refractory ALL received additional treatment with an yttrium-90-labelled anti-CD45+antibody before HSCT2. Given the high variability among patients relapsing after an allogeneic HSCT1, further individual modifications of the original protocol were undertaken in the last part of the conditioning treatment by substituting disease-specific chemotherapy for low-dose TBI in 18 patients ( Figure 1 , Table 1 ).
Postgrafting immunosuppression could be administered according to the protocol in 18 patients. In one patient, tacrolimus could not be started because of acute renal failure, and one patient died before day +5.
Engraftment, chimerism and immune reconstitution No primary graft rejection was observed. Neutrophil engraftment was achieved in 17 patients (85%) within a median of 29 days (range 17-90), while 3 patients died from aplasia. Primary engraftment of platelets was achieved in 12 patients (60%) within a median of 31 days (range 19-142). Patients without neutrophil and/or platelet engraftment suffered from severe infections (n = 5) and/or refractory disease (n = 3).
By day +30, +100 and +360, complete peripheral blood and BM chimerism was observed in 13 (65%), 10 (50%) and 7 (37%) patients, respectively. One patient with refractory AML after matched unrelated HSCT1 showed a mixed chimerism without engraftment at day +30. Loss of chimerism after day +30 was uniformly associated with relapse in seven patients.
For the recovery of the T-cell subsets, the following was notable: CD4+ T-cells already reached median counts >200/μL on day +100 (254/μL; range 60-430) and achieved an almost normal level on day+360 after HSCT2 (median: 430/μL; range 50-770), while median counts of CD8+T-cells were possibly compensatory higher with 480/μL (range 10-2440) on day +100 after HSCT2. Accompanying T-cell lymphopenia, we observed an expansion of natural killer cells at day +100 (median count 240/μL; range 50-1330). Recovery of lymphocyte subsets is shown in Figure 2 . Second HSCT after a first allogeneic transplantation J Tischer et al GvHD Twelve patients (60%) developed aGvHD grade I-IV, which was severe in three cases (grade III, n = 2; grade IV n = 1). Median day of onset of aGvHD was day+24 (range 19-47). The skin was affected in all cases, four patients additionally suffered from liver (n = 2) or liver and gut (n = 2) involvement. cGvHD was observed in five patients and was mild (n = 3) or moderate (n = 2) with the aspect of late aGvHD and overlap syndrome in one patient each.
Infection and toxicity Infectious complications affected 19 patients (95%), with at least one episode of neutropenic fever in 70%. Five and two patients suffered from bacteriemia with coagulase-negative staphylococcus and pseudomonas species, respectively. Seven patients had clinical and radiological signs of pneumonia with detection of aspergillus in the bronchoalveolar lavage in five patients, proving invasive fungal infection (IFI). IFI was lethal in four patients before day +100. Virus reactivation or infection occurred in 45%. No posttransplant lymphoproliferative disorder was observed (Table 2) . Mucositis was the most frequent grade III-IV toxicity, affecting 30% of patients. Renal failure requiring hemodialysis occurred in six patients, five of them showing in parallel other severe complication, such as severe aGvHD and multi-organ failure. Further toxicities (grade III-IV) were hyperbilirubinemia and (Table 3 ). There was no case of sinusoid-obstruction syndrome.
Disease response, survival and NRM Before the start of cytoreductive chemotherapy, 17/20 patients had suffered from refractory, active disease or aplasia. As all patients developed severe aplasia after cytoreductive chemotherapy, no BM aspiration was performed to assess the immediate response at this step of the treatment. After HSCT2, 15 patients (75%) achieved CR/CRi on day +30. Reasons for treatment failure were early death due to infection and toxicity (n = 2), refractory leukaemia (n = 1), IFI (n = 1) and persistent aplasia along with disseminated adenovirus disease and mixed chimerism (n = 1). After a median follow-up of 17 months (range 10-38), seven patients had relapsed at a median of 4.9 months (range 1-13.7). Fourteen patients had died. Causes of death were leukaemic relapse in 6 and transplant-related reasons (NRM; infections, alone (n = 3) or in combination with either GvHD (n = 3) or acute toxicity (n = 2)) in 8 patients. Cumulative incidence of NRM was 10% (95% confidenc interval (CI) 3-34) by day +30 and 36% (95% CI 19-41) by day +100 and day+360 after HSCT2.
Estimated OS and RFS at 1 year from HSCT2 were 45% (95% CI 23-65) and 33% (95% CI 14-54), respectively ( Figure 3 ). For patients with a remission duration >6 months after HSCT1, estimated 1-year OS was 64% (95% CI 30-85) as compared with only 22% (95% CI 4-51) for patients with a shorter duration of remission (hazard ratio (HR): 4.9; P = 0.01), while there was no significant difference in 1-year OS for patients either transplanted in CR/CR with incomplete haematological recovery (67%; 95% CI 8-99) or in non-remission (41%; 95% CI 19-63; HR 0.38; P = 0.36) ( Table 4) . DISCUSSION T-cell-replete HLA-haploidentical HSCT2 after RIC and HDCY for postgrafting immunosuppression was used to treat AL relapse after HSCT1. It was aimed at strengthening the allogeneic GvL reaction both by the haploidentical setting and by changing to a different donor for HSCT2. Patients were in advanced and refractory stage of their disease, frequently with short remission time after HSCT1, and had a high risk of both NRM and death from leukaemia. 8, 9, [25] [26] [27] A high response rate, acceptable toxicity and NRM and a 1-year OS of 45% after HLA-haploidentical HSCT2 points out the feasibility of this approach and justifies further investigation.
The regimen proved to be sufficiently immunosuppressive: no primary graft rejection occurred, whereas graft failure was reported in 6-13% after HLA-haploidentical HSCT using postgrafting HDCY as first transplant. 12, 13 Furthermore, 85% of our patients achieved engraftment, comparable to a 67-97% engraftment rate observed after second HSCT from HLA-matched related or unrelated donors. 10, 25, 26, 28, 29 Additionally, sustained full donor chimerism could be established in all patients with continuing CR, as observed by other studies on HSCT2. 10, 26 Considering our patients' high disease burden, intensive pretreatment and the frequently short median interval after HSCT1, the overall toxicity was moderate. One-third of the patients developed two or more grade III-IV toxicities, mostly involving oral mucosa, liver and kidney, which is comparable to patients receiving sequential cytoreductive therapy and a first allogeneic graft. 17, 30 Veno-occlusive disease (VOD) did not occur in our cohort, whereas Michallet et al. 26 observed VOD in 21% of patients undergoing HSCT2 from the same matched related donor for relapsed leukaemia. Moreover, Radich et al. 31 reported 64% VOD in a cohort of 77 patients with AL undergoing a BU-based myeloablative conditioning without donor change for HSCT2, resulting in a 1-year NRM of 45% and a 1-year RFS of only 14%. Other severe complications such as interstitial pneumonitis, which was reported in 13-21% of the patients after matched related RIC or myeloablative conditioning HSCT2, 26, 31 occurred in only one of our patients.
Infections were the major complication of HLA-haploidentical HSCT2. As described in other alternative transplantation settings, 32, 33 IFI was the most frequent life-threatening infection and a major factor of early mortality. The observed rate of 30% of IFI in our series (all aspergillus spp.) was higher than the 7% reported after T-cell-replete RIC HSCT1, 12 reflecting the high-risk features of our patients, their multiple pretreatments and the Abbreviations: FUO = fever of unknown origin; HHV-6 = human herpesvirus 6; HSCT = haematopoietic SCT; RSV = respiratory syncytial virus. Table 3 . Non-haematological treatment-related toxicity (CTC grade
I-IV)-per patient analysis
Grade I Grade II Grade III Grade IV
GI tract
Constitutional symptoms
Abbreviations: CNS = central nervous system; CTC = common toxicity criteria; GI = gastrointestinal.
Second HSCT after a first allogeneic transplantation J Tischer et al duration and severity of marrow aplasia. Besides the use of PBSC instead of BM to improve early neutrophil engraftment, intensified antifungal primary or secondary prophylaxis and antifungal combination therapy 34 might be considered in this setting, while patients with active fungal disease should possibly not undergo HLA-haploidentical HSCT2. In contrast to IFI, incidence of viral infections (30% CMV reactivation, no post transplant lymphoproliferative disorder) was in a range similar to that observed both after T-cell-replete haploidentical HSCT1 12 and after matched related or unrelated HSCT1 at our institution. 35 This favourable finding may be due to an improved reconstitution of T-cell subsets as observed in our cohort after HSCT2 with a rapid recovery of CD4+ T-cells and natural killer cells by day +100 supported by the use of HDCY post transplantation, which may spare virus-specific memory T-cells while deleting allo-reactive T-cells. 13 Incidence and severity of GvHD resembled results observed after HLA-haploidentical, T-cell-replete first RIC-HSCT. 12, 13 aGvHD and cGvHD were usually mild to moderate, and cGvHD had no influence on outcome in our small cohort, as described elsewhere. 8, 25, 26, 36 Comparable or even higher rates of both aGvHD and cGvHD have been reported from other studies on HSCT2, 9, 36 particularly following donor change. 8, 11 We assume that GvHD was effectively prevented by post-transplant HDCY, tacrolimus and mycophenolate mofetil in our cohort, and thus severe morbidity due to cGvHD, as described by others after RIC HSCT2, 3 was avoided. The observed 1-year NRM of 36% among our patients was similar to the reported rates (23-45%) for HSCT2 using the same donor 8, 26, 29 and at the low end of the range of NRM (35-51%) described for HSCT2 involving donor change. 8, 26, 28, 37 With a CR rate of 75% on day +30, early disease control was satisfying. According to the concept of sequential therapy for HSCT1, 17 we combined cytoreductive chemotherapy with RIC in non-remission patients, which also appeared to be effective in our high-risk HSCT2 cohort. These results are in line with the data of Magenau et al., 30 who observed a CR rate of 80% on day +30 in patients with non-remission haematological malignancies undergoing a sequential therapy, most frequently in preparation for a first, HLA-matched transplantation. A similar early disease control was achieved by HSCT2 from the original HLA-matched donor after RIC using FLAG-Ida for conditioning. 3 However, long-term benefit in that study was limited by relapse and a considerably high rate of cGvHD, leading to severe morbidity, as already described for RIC HSCT1. 38 Although in general the prognosis of leukaemic relapse after HSCT1 is poor, 39, 40 overall outcome in our cohort was encouraging with an OS and RFS of 45% and 33% at 1 year after HSCT2 and compared favourably to earlier studies on HSCT2, demonstrating 1-year OS of 14-20%. 29, 31, 41 Donor change was performed either not at all 31 or ino 20% of the patients. 29, 41 Our results are also comparable to those of the International Bone Marrow Transplant Registry analysis, reporting a 1-year OS of 41% and RFS of 38% for 279 patients relapsing after afirst HLA-matched sibling transplantation, who received HSCT2 from the same HLAmatched donor in 85%. 8 However, in contrast to our cohort, approximately 50% of these patients were aged o 30 years and 29% had CML. Similar results were also observed in smaller series of patients receiving HSCT2 (in most cases, from the same HLAmatched donor), with 1-year OS ranging from 34% to 52% 40, 42, 43 and a RFS of 33%. 40 Recently, Christopeit et al. 11 have reported a 1-year OS of 33% and RFS of 25% from HSCT2 in 179 patients with relapsed AL after matched related (n = 75) or unrelated HSCT1 (n = 104). The median age was 39 years, and 97 patients underwent donor change for HSCT2.
Earlier reports have found that RFS and OS were inversely correlated with patient age and correlated with duration of remission after HSCT1. 8, 9, [25] [26] [27] The duration of remission was often found to be the most significant factor predicting outcome of HSCT2, 8, 9, 25, 26, 28, 31 which was confirmed in our cohort. Given the low patient number, no other risk factors could be identified.
In conclusion, the treatment approach comprising individually designed cytoreduction and RIC, followed by a T-cell replete, HLA-haploidentical second transplant incorporating donor change, was feasible in 20 intensively pre-treated patients with relapsed AL following HSCT1. Successful engraftment and acceptable rates of GvHD, toxicity and NRM were observed, albeit with a rather high rate of IFI. Early outcome was at least comparable to published results after HLA-matched related HSCT2 without donor change, and compared favourably to that of HSCT2 Abbreviations: CI = confidence interval; CRi = CR with incomplete haematological recovery; HSCT = haematopoietic SCT; MRD = matched related donor; URD = unrelated donor. using the same or a different HLA-MUD. To the best of our knowledge, this is the first report on a series of second allogeneic transplantation using HLA-haploidentical donors in adults. Based on the rapid donor availability as compared with MUD, haploidentical HSCT2 might be considered as an alternative treatment option for relapse after HSCT1. Verification in a prospective study with long-term follow-up is warranted.
